From J&J oncology chief to tiny biotech startup CEO? Serge Messerlian talks about his big career changeup
San Francisco-based Teon Therapeutics got itself a new CEO — in a transition from Big Pharma into the world of biotech.
But what sparked that transition isn’t so rosy. The catalyst for the change was when Serge Messerlian’s father passed away last year from renal cancer.
“You know, like those big events in life, people take the opportunity to pause and reflect — which I did,” Messerlian said to Endpoints News. “And I thought it was probably time for me to really get closer to something that I’m very passionate about, which is the science of the life science business. So, I came across Teon as an opportunity.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
